4587 |
Polymer-Free Sirolimus-Eluting Stents in a Large-Scale All-Comers Population |
Soon Jun Hong |
Apr. 28. 18 |
4586 |
Drug Eluting Bioresorbable Mg Scaffold |
Michael Haude |
Apr. 28. 18 |
4585 |
Why BVS Failed |
Stephen G. Ellis |
Apr. 28. 18 |
4584 |
Updated Meta-Analysis of Bioresorbable Scaffolds: Sum Up Many, Many Meta for BRS |
Tullio Palmerini |
Apr. 28. 18 |
4583 |
The Efficacy and Safety of Ticagrelor Versus Clopidogrel in Acute Myocardial Infarction in Taiwan |
Yi-Heng Li |
Apr. 28. 18 |
4582 |
Rethinking DAPT Duration with Smarter DES: Personalized vs. Generalized Strategy |
Davide Capodanno |
Apr. 28. 18 |
4581 |
Proven Secondary Prevention Effect of Ticagrelor from 2017 ESC DAPT Guideline and PEGASUS TIMI-54 |
Joo-Yong Hahn |
Apr. 28. 18 |
4580 |
High Bleeding Risk Patients with DES: Insights from SENIOR and LEADER-FREE Trials |
Marie-Claude Morice |
Apr. 28. 18 |
4579 |
Contemporary Drug Eluting Stents Are Different.: How I Choose DES Type According to Patient/Lesion Features |
Andrejs Erglis |
Apr. 28. 18 |
4578 |
¡°Clinical Outcomes with HBR¡± – LEADERS FREE JAPAN and Angioscopic Findings |
Shimpei Nakatani |
Apr. 28. 18 |